Shandong Sinobioway Biomedicine

Shandong Sinobioway Biomedicine is a China-based biopharmaceutical company focused on biologics, including nerve growth factor products, recombinant interferons, and related biomedicine manufacturing. The company is publicly listed in Shenzhen under ticker 002581 and appears to remain operating, although it has also been referred to in the market as ST Weiming. Its marketed and late-stage assets center on neurotrophic factor products such as mouse nerve growth factor marketed in China, with additional development work in recombinant human nerve growth factor and interferon-based products. Publicly available pipeline intelligence also links the broader Sinobioway group to cell therapy programs including CAR-T studies through affiliated entities. The company combines R&D, pharmaceutical production, and commercial operations in China, with subsidiaries spanning traditional Chinese medicine and biopharmaceutical units.